New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2012
09:00 EDTARII, KALU, CERN, EME, DG, PPG, BSYBY, KFT, IDIX, HMSY, CHK, CMP, CPN, AZN, MDTOn The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: American Railcar (ARII) upgraded to Neutral from Sell at UBS...AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies and to Neutral from Underweight at JPMorgan...Calpine (CPN) upgraded to Buy from Hold at Jefferies...Chesapeake (CHK) upgraded to Outperform from Market Perform at BMO Capital...Compass Minerals (CMP) upgraded to Buy from Hold at KeyBanc...HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies...Idenix (IDIX) upgraded to Market Perform from Underperform at JMP Securities...Kraft Foods (KFT) upgraded to Overweight from Neutral at JPMorgan...British Sky Broadcasting (BSYBY) upgraded to Buy from Neutral at Citigroup...PPG Industries (PPG) upgraded to Outperform from Neutral at Credit Suisse...Dollar General (DG) upgraded to Strong Buy from Outperform at Raymond James...EMCOR Group (EME) upgraded to Buy from Hold at Stifel Nicolaus...Cerner (CERN) upgraded to Outperform from Market Perform at Raymond James...Kaiser Aluminum (KALU) upgraded to Buy from Hold at Dahlman Rose...Medtronic (MDT) upgraded to Buy from Neutral at Lazard Capital.
News For ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT From The Last 14 Days
Check below for free stories on ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 24, 2014
16:09 EDTCERNCerner sees FY14 EPS $1.64-$1.67 vs. previous $1.63-$1.67
Consensus $1.66. Sees FY14 revenue $3.3B-$3.4B vs. previous $3.25B-$3.4B, consensus $3.34B.
16:08 EDTCERNCerner sees Q3 EPS 41c-42c, consensus 42c
Sees Q3 revenue $840M-$870M, consensus $839.94M
16:07 EDTCERNCerner reports Q2 adjusted EPS 40c, consensus 40c
Subscribe for More Information
15:29 EDTCERNNotable companies reporting after market close
Subscribe for More Information
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
06:59 EDTBSYBYBSkyB poised to announce deal to buy Sky Italia, Sky Deutschland, FT reports
Subscribe for More Information
July 23, 2014
16:42 EDTKALUKaiser Aluminum still sees 2014 results as similar to 2012, 2013
Subscribe for More Information
16:41 EDTKALUKaiser Aluminum reports Q2 EPS ex-items $1.05, consensus 87c
Reports Q2 revenue $344.1M, consensus $334.89M.
11:18 EDTARIIDoT proposes phase out of older DOT 111 tank cars for certain flammable liquids
Subscribe for More Information
July 22, 2014
07:38 EDTKALUKaiser Aluminum management to meet with Sterne Agee
Subscribe for More Information
06:37 EDTCPNNRG Energy and Calpine recommended on seasonal weakness at Barclays
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
16:00 EDTDGOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
15:28 EDTCERNCerner August volatility increase into Q2
Cerner August call implied volatility is at 36, September is at 31, December is at 24; compared to its 26-week average of 28 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 22.
13:23 EDTDGHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
07:13 EDTBSYBYFox contemplates using Sky sale to enhance Time Warner offer, Reuters says
Subscribe for More Information
06:58 EDTBSYBYBskyB could buy Murdoch's Sky Italia, Sky Deutschland, Sunday Times says
Subscribe for More Information
06:29 EDTBSYBYBSkyB acquires 70% stake in Love Productions
Subscribe for More Information
July 20, 2014
11:58 EDTCHKCaterpillar, five others should benefit from global recovery, Barron's says
Caterpillar (CAT), Teradata (TDC), Kennametal (KMT), Capital One Financial (COF), T. Rowe Price Group (TROW), and Chesapeake Energy (CHK) are all relatively cheap and should benefit from global recovery, Barron's contends in its cover article. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use